CollaGenex Pharmaceuticals Appoints Klaus Theobald SVP and Chief Medical Officer.Business Editors/Health/Medical Writers NEWTOWN, Pa.--(BUSINESS WIRE)--Jan. 21, 2004 CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI CGPI Corporate Goods Price Index (Japan) CGPI Capital Goods Price Index (New Zealand) ) today announced the appointment of Klaus P. Theobald, M.D., as senior vice president and chief medical officer, effective immediately. Dr. Theobald brings 18 years of clinical and regulatory experience at domestic and international life sciences companies. He has a track record of bringing products to market from concept through approval and a demonstrated ability to work with partners in the U.S., Europe and Japan. He will be responsible for developing future products emerging from CollaGenex's proprietary drug development efforts as well as participating in strategic and tactical aspects of the company's future business development activities. "I am delighted to welcome Dr. Theobald to our management team," stated Colin Stewart The following people are named Colin Stewart
Dr. Theobald joins CollaGenex from Allergenics, Inc., an early-stage biotechnology company focused on oral protein delivery, where he was president and chief executive officer. He previously spent 16 years at Aventis Behring and its predecessor companies in increasingly senior positions, and he most recently served as chief medical officer of Aventis Behring's Genesis Therapeutics subsidiary. During his tenure as vice president, research & development - U.S., of Aventis Behring, Dr. Theobald and his 70-person team negotiated and obtained orphan drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the designation with FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , submitted five INDs and overcame a clinical hold, secured three foreign approvals, and achieved additional labeling claims for four products, in addition to overseeing numerous late-stage clinical trials. Prior to his tenure at Aventis Behring, Dr. Theobald was senior director, worldwide corporate project management, Behringwerke AG, where he managed the transition of the company's R&D organization and obtained approval of new products and additional indications for existing products in the US. He also formerly served as head of clinical research immunology of Behringwerke AG, where he brought four new products to market and obtained re-licensing of 14 additional products. Dr. Theobald received his doctorate in medicine from the Johannes Gutenberg University in Mainz, Germany, where he focused on medical microbiology and immunology. Dr. Theobald will assume the research and development responsibilities previously held by Robert A. Ashley, who will be leaving his position as senior vice president, commercial development of CollaGenex to become chairman, president and chief executive officer of Amplimed Corporation, a privately-held company developing cancer drugs. Mr. Ashley has agreed to serve as a consultant to CollaGenex through the end of the year. CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on providing innovative medical therapies to the dental and dermatology markets. Currently, the Company's 115-person professional dental pharmaceutical sales force markets Periostat(R), which is indicated as an adjunct to scaling and root planing The objective of scaling and root planing, otherwise known as conventional periodontal therapy, is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,[1] for the treatment of adult periodontitis periodontitis Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues. . Periostat(R) is the first and only pharmaceutical to treat periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where by inhibiting the enzymes that destroy periodontal periodontal /peri·odon·tal/ (per?e-o-don´t'l) 1. pertaining to the periodontal ligament or periodontium. 2. near or around a tooth. per·i·o·don·tal adj. 1. support tissues, and by enhancing bone protein synthesis. The sales force also promotes Atridox(R), Atrisorb(R) FreeFlow(TM) and Atrisorb-D FreeFlow, Atrix Laboratories Inc.'s products for the treatment of adult periodontitis to the dental market and Pandel, a prescription, topical corticosteroid corticosteroid /cor·ti·co·ster·oid/ (-ster´oid) any of the steroids elaborated by the adrenal cortex (excluding the sex hormones) or any synthetic equivalents; divided into two major groups, the glucocorticoids and licensed from Altana, Inc., to the dermatology market. Research has shown that certain unique properties of the tetracyclines Tetracyclines Definition Tetracyclines are medicines that kill certain infection-causing microorganisms. Purpose Tetracyclines are called "broad-spectrum" antibiotics, because they can be used to treat a wide variety of discovered during the development of Periostat(R) may be applicable to other diseases involving inflammation and/or destruction of the body's connective tissues, including acne, rosacea Rosacea Definition Rosacea is a skin disease typically appearing in people during their 30s and 40s. It is marked by redness (erythema) of the face, flushing of the skin, and the presence of hard pimples (papules) or pus-filled pimples (pustules), and , meibomianitis and cancer metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to , among others. CollaGenex is further evaluating Periostat(R), as well as the new IMPACS IMPACS Institute for Media, Policy and Civil Society IMPACS Integrated Manufacturing Planning and Control System IMPACS International Message and Packet Switching Service (R) compounds, to assess whether they are safe and effective in these applications, and is nearing completion of a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the to evaluate the use of Periostat to treat rosacea, a dermatological condition. In addition, CollaGenex has licensed the Restoraderm(TM) technology, a unique, proprietary dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. drug delivery system, in order to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties. To receive additional information on the Company, please visit our Web site at www.collagenex.com, which does not form part of this press release. This press release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Investors are cautioned that forward-looking statements involve risks and uncertainties, which may affect the Company's business and prospects. The Company's business of selling, marketing and developing pharmaceutical products is subject to a number of significant risks, including risks relating to the implementation of the Company's sales and marketing plans for Periostat(R) and other products that the Company markets, the outcome and consequences of the patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. against Mutual and the outcome of litigation initiated by Mutual, risks that the FDA will approve generic products, such as Mutual's products, that will compete with and limit the market for Periostat(R), risks inherent in research and development activities, risks associated with conducting business in a highly regulated environment and uncertainty relating to clinical trials of products under development, all as discussed in the Company's periodic filings with the U.S. Securities and Exchange Commission. Periostat(R), IMPACS(R) and Metastat(R) are registered trademarks, and Restoraderm(TM) is a trademark, of CollaGenex Pharmaceuticals, Inc. All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries. Pandel(R) is a trademark of Taisho Pharmaceuticals. Atridox(R) and Atrisorb(R) are registered trademarks, and FreeFlow(TM) is a trademark, of Atrix Laboratories, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion